| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2011PLoSO...622110J |
| P356 | DOI | 10.1371/JOURNAL.PONE.0022110 |
| P932 | PMC publication ID | 3132778 |
| P698 | PubMed publication ID | 21760961 |
| P5875 | ResearchGate publication ID | 51494308 |
| P50 | author | Marcos Estecio | Q41192024 |
| Jean-Pierre J Issa | Q55459879 | ||
| Jorge Eduardo Cortes | Q60320900 | ||
| Hagop Kantarjian | Q60394812 | ||
| Nianxiang Zhang | Q86407993 | ||
| Woonbok Chung | Q92086738 | ||
| Vazganush Gharibyan | Q114428015 | ||
| Kimie Kondo | Q117223256 | ||
| P2093 | author name string | Shoudan Liang | |
| Yue Lu | |||
| Jaroslav Jelinek | |||
| Rong He | |||
| P2860 | cites work | A gene atlas of the mouse and human protein-encoding transcriptomes | Q24568043 |
| DNA methylation profiling of human chromosomes 6, 20 and 22 | Q24607522 | ||
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon alfa | Q28191349 | ||
| Control of developmental regulators by Polycomb in human embryonic stem cells | Q28235841 | ||
| Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome | Q28287810 | ||
| Isolation and functional characterization of a novel organic solute carrier protein, hOSCP1. | Q33218576 | ||
| LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability | Q33283510 | ||
| DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes | Q33628772 | ||
| Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein | Q33682660 | ||
| Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia | Q35871366 | ||
| High-throughput methylation profiling by MCA coupled to CpG island microarray | Q36004673 | ||
| Epigenetic changes in solid and hematopoietic tumors. | Q36279348 | ||
| Correlation between CpG methylation profiles and hormone receptor status in breast cancers | Q36393321 | ||
| Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling | Q36571511 | ||
| Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse | Q36835063 | ||
| Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. | Q37086937 | ||
| Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle | Q37234340 | ||
| Genome-wide screen of promoter methylation identifies novel markers in melanoma. | Q37287368 | ||
| Treatment selection after imatinib resistance in chronic myeloid leukemia | Q37431597 | ||
| Imatinib and beyond--exploring the full potential of targeted therapy for CML. | Q37571446 | ||
| A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers | Q39628888 | ||
| CpG island methylation profiling in human melanoma cell lines. | Q39851708 | ||
| PDLIM4, an actin binding protein, suppresses prostate cancer cell growth | Q39884402 | ||
| Methylation status of RASSF1A in patients with chronic myeloid leukemia | Q39887507 | ||
| Genome-wide identification of aberrantly methylated promoter associated CpG islands in acute lymphocytic leukemia. | Q39975102 | ||
| Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. | Q40085449 | ||
| Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. | Q40459776 | ||
| Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate | Q40508930 | ||
| A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements | Q40587967 | ||
| DNA methylation in serum and tumors of cervical cancer patients | Q40593488 | ||
| Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification | Q40951949 | ||
| The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. | Q41223399 | ||
| Hypermethylation-associated inactivation indicates a tumor suppressor role for p15INK4B. | Q41228119 | ||
| Alterations in DNA methylation: a fundamental aspect of neoplasia | Q41617101 | ||
| Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications | Q41731985 | ||
| Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia | Q43246242 | ||
| Role of the nucleoplasmin 2 C-terminal domain in the formation of nucleolus-like bodies in mouse oocytes | Q43266806 | ||
| Promoter hypomethylation of the LINE-1 retrotransposable elements activates sense/antisense transcription and marks the progression of chronic myeloid leukemia | Q44500993 | ||
| Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets | Q44826936 | ||
| sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia | Q46177631 | ||
| CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia | Q46902022 | ||
| Cloning, expression, and mutation analysis of NOR1, a novel human gene down-regulated in HNE1 nasopharyngeal carcinoma cell line | Q48239551 | ||
| Alterations of DNA methylation and histone modifications contribute to gene silencing in hepatocellular carcinomas. | Q51579451 | ||
| RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. | Q55043439 | ||
| Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia | Q56418625 | ||
| HIC1 hypermethylation is a late event in hematopoietic neoplasms | Q58290208 | ||
| Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies | Q63641308 | ||
| Abnormal methylation of the calcitonin gene marks progression of chronic myelogenous leukemia | Q70167698 | ||
| Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia | Q80979924 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| imatinib | Q177094 | ||
| DNA methylation | Q874745 | ||
| P304 | page(s) | e22110 | |
| P577 | publication date | 2011-07-08 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia | |
| P478 | volume | 6 |
| Q34221688 | A nucleolin-DNMT1 regulatory axis in acute myeloid leukemogenesis |
| Q47308486 | Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma. |
| Q98154704 | Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients |
| Q42583748 | Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. |
| Q37562575 | Analysis of EHMT1 expression and its correlations with clinical significance in esophageal squamous cell cancer |
| Q49593223 | Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia. |
| Q90706502 | BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia |
| Q35067505 | BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia |
| Q39769583 | Biology of CML stem cells: the basis for clinical heterogeneity? |
| Q58102326 | Chronic Myeloid Leukemia: Beyond BCR-ABL1 |
| Q47723259 | Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis |
| Q36484120 | Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique |
| Q42551545 | Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms |
| Q39370931 | Cytoplasmatic compartmentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia |
| Q41198168 | DNA Methylation Fluctuation Induced by Virus Infection Differs between MD-resistant and -susceptible Chickens |
| Q90010439 | DNA Methylome Analysis of Saturated Aliphatic Aldehydes in Pulmonary Toxicity |
| Q54487995 | DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia |
| Q52633239 | DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15- cells in early chronic-phase chronic myeloid leukemia |
| Q38941081 | DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia |
| Q90731731 | Data-Driven-Based Approach to Identifying Differentially Methylated Regions Using Modified 1D Ising Model |
| Q88131390 | Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells |
| Q35645500 | Dissecting the role of aberrant DNA methylation in human leukaemia |
| Q92409425 | Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML |
| Q38209574 | Epigenetic perspectives on cancer chemotherapy response |
| Q51726366 | Expression of oxidored nitro domain-containing protein 1(NOR1) impairs nasopharyngeal carcinoma cells adaptation to hypoxia and inhibits PDK1 expression |
| Q37625352 | G0S2 inhibits the proliferation of K562 cells by interacting with nucleolin in the cytosol |
| Q33632450 | GPU-BSM: a GPU-based tool to map bisulfite-treated reads |
| Q35919012 | GPX3 promoter is methylated in chronic myeloid leukemia. |
| Q33585130 | Genome-wide signatures of differential DNA methylation in pediatric acute lymphoblastic leukemia |
| Q41483822 | HOXA4Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients |
| Q38845834 | How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety |
| Q37376261 | Identification of hypermethylation in hepatocyte cell adhesion molecule gene promoter region in bladder carcinoma |
| Q64096510 | Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function? |
| Q52761621 | Impact of Chromosomal Rearrangement upon DNA Methylation Patterns in Leukemia |
| Q52683084 | Inactivation of Receptor Tyrosine Kinases Reverts Aberrant DNA Methylation in Acute Myeloid Leukemia |
| Q41955151 | Lineage-specific function of Engrailed-2 in the progression of chronic myelogenous leukemia to T-cell blast crisis. |
| Q91812801 | Mechanisms of Disease Progression and Resistance to Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia: An Update |
| Q47165781 | MicroRNA-212/ABCG2-axis contributes to development of imatinib-resistance in leukemic cells. |
| Q84220622 | Molecular biology of chronic myeloid leukemia |
| Q42330162 | Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia |
| Q53751456 | Regulatory network analysis of microRNAs and genes in imatinib-resistant chronic myeloid leukemia |
| Q38072315 | Role of epigenetics in chronic myeloid leukemia |
| Q37086113 | Significance of the NOR1-FOXA1/HDAC2-Slug regulatory network in epithelial-mesenchymal transition of tumor cells |
| Q91898953 | Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors |
| Q44013589 | TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer |
| Q27313466 | The DNA Methyltransferase DNMT1 and Tyrosine-Protein Kinase KIT Cooperatively Promote Resistance to 5-Aza-2'-deoxycytidine (Decitabine) and Midostaurin (PKC412) in Lung Cancer Cells |
| Q37726411 | The NOR1/OSCP1 proteins in cancer: from epigenetic silencing to functional characterization of a novel tumor suppressor |
| Q37593435 | Therapy of chronic myeloid leukemia: twilight of the imatinib era? |
| Q39129511 | Tumor suppressor gene Oxidored-nitro domain-containing protein 1 regulates nasopharyngeal cancer cell autophagy, metabolism, and apoptosis in vitro |
| Q48303173 | Tumor suppressor gene methylation on the short arm of chromosome 1 in chronic myelogenous leukemia. |
| Q38684564 | Using Epigenetic Therapy to Overcome Chemotherapy Resistance. |